Pharvaris NV

More Details of Pharvaris NV Company

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Company Info

Ticker SymbolPHVS

Company namePharvaris NV

IPO dateFeb 05, 2021

Founded at2015

CEOMr. Berndt Modig, CPA

Number of employees- -

Security typeOrdinary Share

Fiscal year-endFeb 05

AddressEmmy Noetherweg 2

CityLEIDEN

Stock exchangeNASDAQ Global Select Consolidated

CountryNetherlands

Postal code2333 BK

Phone31712036410

Websitehttps://pharvaris.com/

Ticker SymbolPHVS

IPO dateFeb 05, 2021

Founded at2015

Company Executives

Name

Name/Position

Position

Shareholding

Change

Dr. David P. Meeker, M.D.

Non-Executive Director

102.82K

-15.53%

Ms. Viviane Monges

Non-Executive Director

54.91K

+73.10%

Ms. Anna Nijdam

Head of Finance, Principal Accounting Officer

50.54K

+0.63%

Dr. Elisabeth Bjork, M.D., Ph.D.

Non-Executive Director

50.53K

+128.70%

Mr. David W. Nassif, J.D.

Chief Financial Officer

800.00

--

Dr. Jochen Knolle, Ph.D.

Co-Founder, Chief Operating Officer, Chief Scientific Officer

--

Dr. Peng Lu, M.D., Ph.D.

Chief Medical Officer

--

Dr. Anne Marie De Jonge Schuermans, Ph.D.

Non-Executive Director

--

Mr. Berndt Modig, CPA

Chief Executive Officer, Co-Founder, Executive Director

--

Dr. Morgan Conn, Ph.D.

Chief Business Officer

--

Name

Name/Position

Position

Shareholding

Change

Dr. David P. Meeker, M.D.

Non-Executive Director

102.82K

-15.53%

Ms. Viviane Monges

Non-Executive Director

54.91K

+73.10%

Ms. Anna Nijdam

Head of Finance, Principal Accounting Officer

50.54K

+0.63%

Dr. Elisabeth Bjork, M.D., Ph.D.

Non-Executive Director

50.53K

+128.70%

Mr. David W. Nassif, J.D.

Chief Financial Officer

800.00

--

Dr. Jochen Knolle, Ph.D.

Co-Founder, Chief Operating Officer, Chief Scientific Officer

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Thu, May 15

Shareholders

Shareholder Types

Shareholders

Proportion

General Atlantic LLC

13.82%

Fidelity Management & Research Company LLC

9.90%

Foresite Capital Management, LLC

8.09%

VenBio Partners LLC

7.87%

Viking Global Investors LP

6.70%

Other

53.61%

Shareholders

Proportion

General Atlantic LLC

13.82%

Fidelity Management & Research Company LLC

9.90%

Foresite Capital Management, LLC

8.09%

VenBio Partners LLC

7.87%

Viking Global Investors LP

6.70%

Other

53.61%

Shareholder Types

Shareholders

Proportion

Private Equity

30.24%

Investment Advisor

18.67%

Venture Capital

17.96%

Hedge Fund

15.17%

Investment Advisor/Hedge Fund

7.22%

Individual Investor

6.25%

Research Firm

0.15%

Bank and Trust

0.05%

Pension Fund

0.04%

Other

4.26%

Institutional Shareholding

Updated: Tue, Jul 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q2

124

52.17M

95.74%

-1.39M

2025Q1

125

53.89M

99.06%

+200.61K

2024Q4

123

53.45M

98.98%

+218.03K

2024Q3

114

53.86M

99.73%

+1.03M

2024Q2

83

52.08M

96.43%

-141.66K

2024Q1

76

49.63M

98.30%

-831.88K

2023Q4

69

47.76M

94.74%

+8.60M

2023Q3

54

36.05M

91.51%

-2.92M

2023Q2

53

35.78M

91.11%

+3.65M

2023Q1

61

28.67M

84.75%

-3.62M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

General Atlantic LLC

7.53M

13.82%

--

Mar 31, 2025

Fidelity Management & Research Company LLC

5.40M

9.9%

--

Mar 31, 2025

Foresite Capital Management, LLC

4.41M

8.09%

+12.70K

+0.29%

Mar 31, 2025

VenBio Partners LLC

4.29M

7.87%

--

Mar 31, 2025

Viking Global Investors LP

3.65M

6.7%

--

Mar 31, 2025

EQT Life Sciences

3.56M

6.53%

--

Apr 01, 2025

Bain Capital Life Sciences Investors, LLC

3.30M

6.06%

--

Mar 31, 2025

VR Adviser, LLC

3.11M

5.71%

-107.41K

-3.34%

Mar 31, 2025

Deerfield Management Company, L.P.

2.02M

3.7%

--

Mar 31, 2025

Commodore Capital LP

1.91M

3.51%

--

Mar 31, 2025

Related ETFs

Updated: Sun, Jul 6

Name

Proportion

Virtus LifeSci Biotech Clinical Trials ETF

0.96%

ALPS Medical Breakthroughs ETF

0.73%

iShares MSCI Netherlands ETF

0.1%

iShares MSCI Europe Small-Cap ETF

0.02%

SPDR S&P International Small Cap ETF

0.02%

iShares MSCI EAFE Small-Cap ETF

0.01%

Avantis International Small Cap Equity ETF

0.01%

First Trust IPOX Europe Equity Opportunities ETF

0%

Xtrackers MSCI Eurozone Hedged Eqty ETF

0%

Virtus LifeSci Biotech Clinical Trials ETF

Proportion0.96%

ALPS Medical Breakthroughs ETF

Proportion0.73%

iShares MSCI Netherlands ETF

Proportion0.1%

iShares MSCI Europe Small-Cap ETF

Proportion0.02%

SPDR S&P International Small Cap ETF

Proportion0.02%

iShares MSCI EAFE Small-Cap ETF

Proportion0.01%

Avantis International Small Cap Equity ETF

Proportion0.01%

First Trust IPOX Europe Equity Opportunities ETF

Proportion0%

Xtrackers MSCI Eurozone Hedged Eqty ETF

Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

25.120USD

Pharvaris NV

25.120

Overview

Company

Financials